[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100374584":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":42,"responsibleParty":62,"collaborators":64,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":10,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"The Institute of Molecular and Translational Medicine, Czech Republic","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Asthma",null,"Children\u002Fadults with moderate or IgE mediated asthma with inhaled and\u002For food allergies before and during inhaled corticosteroid, leukotriene modifiers or long-acting beta agonists treatment.",[13],"Diagnostic Test: Collection of breath condensate",{"label":15,"type":10,"description":16,"interventionNames":17},"Cystic fibrosis","Children\u002Fadults with cystic fibrosis before and after antibiotics treatment and during clinical deterioration.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Healthy control","Healthy control children\u002Fadults without chronic or autoimmune disease",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","Collection of breath condensate","Breath condensate will be collected from the patients involved in study.",[9,15,19],[29],{"name":30,"affiliation":5,"role":31},"Petr Dzubak, MD, PhD.","STUDY_DIRECTOR",[33,38],{"name":30,"role":34,"phone":35,"phoneExt":36,"email":37},"CONTACT","585632150","+420","petr.dzubak@upol.cz",{"name":39,"role":34,"phone":40,"phoneExt":36,"email":41},"Marian Hajduch, MD, PhD","585632","marian.hajduch@upol.cz",[43],{"facility":44,"status":45,"city":46,"state":10,"zip":47,"country":48,"countryCode":10,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"University Hospital Olomouc","RECRUITING","Olomouc","77900","Czechia",{"type":50,"coordinates":51},"Point",[52,53],17.25175,49.59552,{"lat":53,"lon":52},[56,59],{"name":57,"role":34,"phone":58,"phoneExt":10,"email":37},"Petr Dzubak, MD, PhD","+420 585632150",{"name":60,"role":34,"phone":61,"phoneExt":10,"email":41},"Marian Hadjuch, MD, PhD","+420 585632082",{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[65],{"name":44,"class":6},"100374584","pulmonary-condensate-non-invasive-evaluation-of-pulmonary-involvement-in-asthma-and-cystic-fibrosis-100374584",false,"NCT04157361","Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.","Pulmonary Condensate: A Promising Source of Proteomic Biomarkers for Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.","Inclusion Criteria:\n\n* Children\u002Fadults with moderate or IgE mediated asthma\n* Children\u002Fadults with cystic fibrosis\n* Healthy control children\u002Fadults without lung disorders\n\nExclusion Criteria:\n\n\\-",true,"ALL",{"count":76,"type":77},450,"ESTIMATED","OBSERVATIONAL","Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like (CF) Cystic fibrosis or (AB) Bronchial asthma would be highly beneficial. Investigators propose to establish EBC \"breathprints\" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.",[81,82],"Bronchial Asthma","Pulmonary Cystic Fibrosis",[84,85,86],"Breath condensate","Bronchial asthma","Cystic Fibrosis","2026-03-19",{"date":89,"type":90},"2026-03-23","ACTUAL",{"date":92,"type":90},"2015-05-01",{"date":94,"type":77},"2026-12-31",{"name":5,"class":6},1]